Ferreira, Nilson C.
Campos, Alline C.
Guimaraes, Francisco S.
Zimmermann, Patricia M. da R.
Brum Junior, Liberato
Hallak, Jaime E.
Crippa, Jose A.
Zuardi, Antonio W.
Total Authors: 9
 Univ Sao Paulo, FMRP, Dept Farmacol, Ribeirao Preto, SP - Brazil
 Univ Sao Paulo, Dept Morfol Fisiol & Patol Bas, FORP, Ribeirao Preto, SP - Brazil
 Prati Donaduzzi & Cia Ltda, Toledo, PR - Brazil
 Univ Sao Paulo, Dept Neurociencias & Ciencias Comportamento, FMRP, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP - Brazil
Total Affiliations: 4
Revista Brasileira de Psiquiatria;
Web of Science Citations:
Current pharmacotherapy of Parkinson's disease (PD) is palliative and unable to modify the progression of neurodegeneration. Treatments that can improve patients' quality of life with fewer side effects are needed, but not yet available. Cannabidiol (CBD), the major non-psychotomimetic constituent of cannabis, has received considerable research attention in the last decade. In this context, we aimed to critically review the literature on potential therapeutic effects of CBD in PD and discuss clinical and preclinical evidence supporting the putative neuroprotective mechanisms of CBD. We searched MEDLINE (via PubMed) for indexed articles published in English from inception to 2019. The following keywords were used: cannabis; cannabidiol and neuroprotection; endocannabinoids and basal ganglia; Parkinson's animal models; Parkinson's history; Parkinson's and cannabidiol. Few studies addressed the biological bases for the purported effects of CBD on PD. Six preclinical studies showed neuroprotective effects, while three targeted the antidyskinetic effects of CBD. Three human studies have tested CBD in patients with PD: an open-label study, a case series, and a randomized controlled trial. These studies reported therapeutic effects of CBD on non-motor symptoms. Additional research is needed to elucidate the potential effectiveness of CBD in PD and the underlying mechanisms involved. (AU)